



CERTIFICATE OF MAILING

be hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to

Assistant Commissioner for Patents
Washington, D.C. 20231

On

10/11/02

DELTAGEN, INC.

By

Deborah A. Mojarrro

Deborah A. Mojarrro

PATENT
Attorney Docket No.: R-126

RECEIVED

OCT 21 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CATHERINE GUENTHER et al.

Application No.: 09/883,093

Filed: June 14, 2001

For: Transgenic Mice Containing Nuclear
Hormone Receptor Gene Disruptions

Examiner: Unassigned

Art Unit: 1646

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached Form PTO/SB/08A are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


This Information Disclosure Statement as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits. Each item contained in the information disclosure statement was cited in an International Search Report (copy enclosed) mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR § 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR § 1.98 and MPEP § 609 and the Examiner is respectfully requested to consider the listed references.


The Commissioner is hereby authorized to charge our Deposit Account No. 50-1271 for any fees required in connection with the filing of this Information Disclosure Statement. **A duplicate copy of this Notice is enclosed for this purpose.** In particular, in the event that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is authorized to charge the above-named deposit account for any fees required pursuant to CFR § 1.17(p) or § 1.17(i)(1).

Respectfully submitted,


Mariette A. Lapiz, Reg. No. 44,202

DELTAGEN, INC.
740 Bay Road
Redwood City, CA 94063
Tel: 650-569-5100
Fax: 650-569-5280

MAL/dam



OCT 17 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO SB.08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

RECEIVED

Page 21 2022

TECH CENTER 1680/2900

Application Number 09/883,093

Filing Date June 14, 2001

First Named Inventor GUENTHER

Art Unit 1646

Examiner Name Unass

Attorney Docket Number R-126

Attorney Docket Number R-126

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
B	WO	96/35785	A2	11/14/1996	KARO BIO AB	Claims 1, 7, 8	
C	WO	94/26100	A1	11/24/1994	INST. NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE et al.	Claim 1	
D	WO	01/51045	A2	07/19/2001	TULARIK INC.	Example 6	
E	WO	02/25270	A1	03/28/2002	BAYLOR COLLEGE OF MEDICINE	Claims 3-5	
F	WO	99/15555	A1	04/01/1999	THE GENERAL HOSPITAL CORP.	Claims 1, 3	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Applicant's unique citation designation number (**optional**) ² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2 0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unsaved Document